Discontinuation of warfarin therapy higher than generally anticipated
October 29th 2012Among older adults with atrial fibrillation (AF), persistence with warfarin therapy is generally lower than what has been reported in clinical trials, according study online in Archives of Internal Medicine.
Read More
FDA approves Synribo for chronic myelogenous leukemia
October 26th 2012FDA has approved omacetaxine mepesuccinate (Synribo, Teva) to treat adults with chronic myelogenous leukemia (CML), a blood and bone marrow disease. An estimated 5,430 people will be diagnosed with CML in 2012, according to the National Institutes of Health. Synribo is intended to be used in patients whose cancer progressed after treatment with at least 2 drugs from a class called tyrosine kinase inhibitors (TKIs), also used to treat CML.
Read More
ACIP recommends bacterial meningitis vaccine for at-risk infants
October 25th 2012The Advisory Committee for Immunization Practices (ACIP) voted to recommend the use of Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine (MenHibrix, GlaxoSmithKline) in infants at increased risk for bacterial meningitis.
Read More
Mass. DPH finds multiple health, safety violations at NECC
October 24th 2012Numerous health and safety violations related to the practice of pharmacy at the New England Compounding Center (NECC), Framingham, Mass. have been documented by investigators of the Massachusetts Department of Public Health (DPH), according to Madeleine Biondolillo, MD, in a press conference Oct. 23
Read More
Investigational drugs to be studied for preventing Alzheimer's
October 23rd 2012Three investigational drugs will be studied in a worldwide clinical trial to determine whether they can prevent Alzheimer’s disease. In people with inherited mutations that cause early-onset Alzheimer’s, the study will seek to identify whether the drugs can improve Alzheimer’s disease biomarkers and prevent the loss of cognitive function.
Read More
FDA confirms specific fungus associated with meningitis outbreak
October 19th 2012FDA and the Centers for Disease Control and Prevention (CDC) confirm that the fungus Exserohilum rostratum contaminated 1 of the 3 implicated lots of preservative-free methylprednisolone acetate (80 mg/mL) from the New England Compounding Center (NECC), which the company recalled September 26.
Read More
FDA expands use of Actemra for earlier-stage arthritis
October 15th 2012FDA has expanded the approved indication for tocilizumab (Actemra, Genentech) for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to 1 or more disease-modifying antirheumatic drugs (DMARDs).
Read More
Social value of statins merits actions to broaden treatment, improve adherence, study finds
October 15th 2012New evidence suggests that statins generate large survival and health benefits at the population level and shows that the social value of the survival gains are large and go predominantly to consumers, according to a study published in the October issue of Health Affairs.
Read More
First universal medication labeling standards may lead to better adherence
October 11th 2012With medication misuse resulting in more than 1 million adverse drug events per year in the United States, new standards released today by the U.S. Pharmacopeia Convention (USP) for the first time, provide a universal approach to the format, appearance, content, and language of instructions for medicines in containers dispensed by pharmacists.
Read More
Generic antidepressant taken off the market
October 8th 2012After reviewing new data, FDA has concluded that Budeprion XL 300 mg (bupropion hydrochloride extended-release tablets), manufactured by Impax Laboratories, Inc., and marketed by Teva Pharmaceuticals USA, Inc., is not therapeutically equivalent to GlaxoSmithKline’s Wellbutrin XL 300 mg.
Read More